- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01526915
Assessment of Platelet Rich Fibrin Efficiency on Healing Delay and on Jawbone Osteochemonecrosis Provoked by Bisphosphonates (OCN/PRF)
Contribution of Platelet Rich Fibrin (PRF) After Tooth Avulsion in the Prevention of Healing Delay and of Jawbone Osteochemonecrosis Induced by Bisphosphonates
Study Overview
Status
Intervention / Treatment
Detailed Description
Scientific Context Bisphosphonates (BP) work by slowing down bone remodelling. They are used in the management of different types of cancers and for the treatment of osteoporosis. Recent studies warned that this drug could produce adverse effects on jawbones .In December 2007, the AFSSAPS (French agency for the Sanitary Security of Health Products) alerted the health professionals about the risks of spontaneous or induced osteonecrosis following invasive odontological procedures on patients receiving BP. Prevalence of these osteonecrosis varies from 6% to 10% after surgical intervention. A healing delay estimated between 20 to 25% of cases frequently precedes the occurrence of osteochemonecrosis.
On the whole , the total rate of all complications amounts to 30%. We are extremely limited in terms of prevention or treatment of an OCN patient. We intend to study a biological autologous sediment obtained from a blood sample for its capacity to avoid these complications supervening. The collection of a coagulum called Platelet Rich Fibrin or PRF susceptible to provide the essential ingredients for the mucous membrane and the bone healing is obtained by centrifugation. This biomaterial rich in autologous fibrin is a concentrate of leukocytes, platelets and a number of factors favouring cicatrisation and immune response. Clinical applications are already well documented in orthopaedic, thoracic and cardiac surgeries and, also in dermatology. The use of PRF in dental surgery is more recent. Literature on this topic is very limited but these new techniques give rise to high hopes. Since February 2007,thanks to the classification as a medical treatment by the AFSSAPS, the PRF technique has been authorized.
Objectives To appraise after dental avulsion the PRF efficiency in preventing delay of cicatrisation and jawbone osteochemonecrosis induced by BP.
This efficiency will be assessed by a retroalveolar X-ray performed at each visit. The main criteria for evaluation is the discovery of cicatrisation delay at week 8 and/or osteochemonecrosis during the follow up.
Material and methods
Studied population: current or previous patients treated with BP and referred for a dental avulsion.
General experimental procedure: A prospective, longitudinal, multicentric, randomized open study. Patients will be randomized into two groups: dental avulsion only or dental avulsion and PRF. For both groups the initial management is surgical (bone curettage + PRF for the PRF group).The follow up is spread over one year with 10 visits. Each patient will undergo a clinical and photographic examination with a complete radiological check up(OPT),a standard biological blood test (blood count with haemogram (NFS) and a thorough calculation of the quantity of BP administered. The appearance of OCN or of any delay in cicatrisation will be documented by a histological biopsy, a bacteriological swab test and X-ray.
The requisite number of patients:
270 patients are required to validate the expected objectives in this study. Their recruitment will take place in 4 establishments: Metz-Thionville CHR (Regional Central Hospital) and three university teaching hospitals (CHU) Dijon, Nancy and Reims.
Total Duration of the study :
The estimated total duration will be 3 years: a 2 year recruitment with a 1 year follow-up.
Expected results and prospects To prove the interest of using PRF as a therapy able to prevent a delay in cicatrization or an OCN induced by BP.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dijon, France, 21033
- CHU de Dijon
-
Maxeville, France, 54320
- Scm Bally Curien
-
Metz, France, 57038
- CHR Metz Thionville
-
Nancy, France, 54035
- Chu de Nancy
-
Reims, France, 51092
- CHU de Reims
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient major(male or female)
- Documented indication at the initial visit at day 0 (JO) for a maximum extraction of 3 teeth.
Treatment with nitrogenous or non-nitrogenous BP by intravenous injection or oral administration whichever the reason for this drug prescription:
- on going BP treatment
- patient having received a previous treatment with bisphosphonates (irrespective of the duration and withdrawal date of this treatment)
- Patient having received the specific information letter regarding the study and having signed the clarified consent form.
Exclusion Criteria:
- Patient having a maxillary or mandibulary OCN at Day 0(JO)
- Positive HIV serology at Day 0(for patients belonging to the PRF group)
- Previous history of maxillo-cervico-facial radiotherapy
- Patients with estimated survival expectancy shorter than one year
- Lack of social security cover
- Inability of the patient to respect the study follow-up
- Patient having reached his/her majority and under tutelage,trusteeship or protection of the court
- Patient whose diagnosis could not be revealed to him/her (especially when the patient or their family expressed this wish).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bone curettage + PRF
Bone curettage and PRF insertion
|
Bone curettage and PRF insertion
|
Other: Bone curettage alone
Bone curettage without PRF insertion
|
Bone curettage without PRF insertion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Delay in cicatrisation at week 8
Time Frame: 8 weeks
|
8 weeks
|
The appearance of osteochemonecrosis during the follow-up period
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The characteristics of the received BP treatment: starting date of ongoing treatment, accumulated dose, type of BP, administration route
Time Frame: 1 year
|
1 year
|
The precise location of the extraction site according to the tooth classification number
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Eric GERARD, Dr, CHR Metz Thionville
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RBM 2009-01
- 2009-A01003-54 (Other Identifier: ID RCB - AFSSAPS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Jawbone Osteochemonecrosis Induced by Bisphosphonates
-
Novartis PharmaceuticalsCompletedProstate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated
-
Instituto de Investigación Hospital Universitario...UnknownCardiovascular Toxicity Induced by Antitumoral DrugsSpain
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbTerminatedSolid Tumors Induced by Prior Radiation ExposureUnited States
-
University of AarhusThe Ministry of Science, Technology and Innovation, DenmarkCompletedWhole Body Catabolisme Induced by GlucocorticoidsDenmark
-
Assiut UniversityCompletedDrug-Induced Liver InjuryEgypt
-
Korea Institute of Radiological & Medical SciencesActive, not recruitingRadiation Effects | Neoplasms, Radiation-Induced | Occupational Exposure to Radiation | Leukemia, Radiation-InducedKorea, Republic of
-
University Hospital, BordeauxRegional Health Agency New AquitaineCompletedPoisoning by Psychoactive SubstancesFrance
-
King Chulalongkorn Memorial HospitalCompletedGastric Ulcer Induced by Anti-platelet Agent | Duodenal Ulcer Induced by Anti-platelet AgentThailand
-
Ai PengCompletedPoisoning by Paraquat With Undetermined IntentChina
-
The University of Hong KongTerminatedGastric Ulcer Induced by Anti-platelet Agent | Duodenal Ulcer Induced by Anti-platelet Agent | OGDChina, Hong Kong
Clinical Trials on Bone curettage + PRF
-
Bispebjerg HospitalCompletedKeratosis, ActinicDenmark
-
Second Affiliated Hospital, School of Medicine,...RecruitingBone Loss, AlveolarChina
-
Zeynep Kamil Maternity and Pediatric Research and...UnknownEndometrial DiseaseTurkey
-
Al-Azhar UniversityNot yet recruitingSticky Bone | iPRF | Periodontal DefectEgypt
-
State University of New York - Upstate Medical...Stryker Trauma GmbH; Stryker NordicCompletedBone Lesion
-
Future University in EgyptCompleted
-
Istanbul UniversityWithdrawn
-
Saint Thomas Hospital, PanamaCompletedEclampsia | Pre-EclampsiaPanama
-
Meenakshi Ammal Dental College and HospitalCompletedPeriodontal Bone Loss | Periodontal Disease | Osteoclastic Bone Loss
-
Istituto Ortopedico RizzoliCompletedChondrosarcoma | Chondroma